XCHC Announces Appointment of Doctorandus Mario Lap as Director of European Operations, as the Company Solidifies Expansion in Europe for Immediate Product Release to European and North American Consumers

AMSTERDAM, May 8, 2013 /PRNewswire/ -- X-Change Corp (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health solutions is pleased to announce the appointment of drs. Mario Lap as Director of European Operations for the Company and several Dutch subsidiaries that are being formed by the Company in the Netherlands.  Mr. Lap brings to the Company a unique combination of expertise in Dutch and greater European medical cannabis law and policy as well as in the areas of health care, IT security, law enforcement, and government relations. Mr. Lap has written numerous international papers and legislative initiatives regarding medical and non-medicinal cannabis laws and access throughout Europe.  Mr. Lap has made several television and radio appearances on CNN, BBC, France 2, RTL, and various Dutch public and commercial channels to give public education and information on policy, laws, and current medical breakthroughs.

Mr. Lap, a Dutch health and IT regulatory lawyer in Amsterdam, has extensive experience in Europe with health care and drug policy, medical cannabis regulation, substance use policy, IT project management, digital security policy, food and medicine regulation, and other governmental and private sector consulting.  Mr. Lap currently serves as Director, Foundation on Drug Policy and Human Rights, and Director, Drugtext Foundation, and as a Director of various private ventures.  Mr. Lap also served as Director of Sales of Apcare B.V., Director of Yalado International B.V., Founder and Director, Calyx Internet B.V. and Calyx Internet Corporation, Professor at the Rechercheschool (Dutch National Police Academy), Head of the Legal and Policy Department of the Netherlands Institute on Alcohol and Other Drugs, and Head of Legal and Policy Department, and Pilot Project of European Monitoring Center on Drugs and Drug Addiction.

Mr. Lap, has an extensive educational background through studies at the Het Amsterdams Lyceum, Colloqium Doctum University of Amsterdam, University of Amsterdam Law School, Open University and University of Liverpool, and speaks fluent Dutch, English, French, and German. 

"We are incredibly fortunate to announce that Mario Lap has joined the XCHC team, operating from his home base in Amsterdam.  A person of Mario's caliber is nearly impossible to find.  His varied professional experience and vast European network will undoubtedly prove beneficial to the success of the Company's operations in Europe and, I believe, beyond," stated Chad Johnson, Esq., Chief Operating Officer and General Counsel of X-Change Corp.

About The X-Change Corporation

X-Change Corp is U.S. Boutique Company whose niche is cannabinoid based extracts and product lines that target critical ailments through State-by-State and International regulatory guidelines, the cosmeceutical/nutraceutical market for mid-tier product lines, such as Phytiva, and new social usage initiatives. These product lines will be launched through a combination of retail and wholesale outlets, medical cannabis dispensaries, cannabis research/treatment clinics, laboratories, and other government regulated distribution channels on a jurisdictional basis internationally.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

X-Change Corp.
President & CEO
Robert Kane
[email protected]
www.phytiva.com
1.866.326.5595

SOURCE X-Change Corp